Biointron Weekly Reports
News???
Thank you to all who visited our booth at the 12th Annual Immuno-Oncology Summit 2024 hosted by Cambridge Healthtech Institute last week in Philadelphia! We had a great time chatting with you and have prepared highlights of the event here.??
?? Join our next webinar: “Accelerating Antibody Drug Discovery with Fully Human Antibody Mouse HUGO-Ab and High-Throughput Single B Cell Screening”, on November 9, 9PM EST // November 10, 9AM Beijing Time.
In our latest episode of the new Antibody ABCs video series, we define phage display. Watch it now.??
?
This Week’s News?
Trends – VHH Antibodies Everywhere
VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~?15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!
This week, researchers from the U.S. Naval Research Laboratory published a paper on TEMPRO, a novel predictive modeling approach for estimating the melting temperature (Tm) of VHH antibodies using computational methods. TEMPRO integrates biophysical features such as Evolutionary Scale Modeling (ESM) embeddings, NetSurfP3 structural predictions, pLDDT scores from AlphaFold2, and sequence physicochemical characteristics to predict Tm. Further validation confirmed its reliability, making TEMPRO a valuable tool for optimizing VHH antibodies and highlighting the potential of protein embeddings in enhancing downstream protein analyses.
Meanwhile, researchers from 南京大学 demonstrated the efficacy of anti-CD4 trimeric VHH antibodies in inhibiting HIV-1 infection by inducing CD4 conformational alteration. CD4, pivotal for HIV-1 entry, poses challenges for drug development due to neutralization and cytotoxicity concerns. Strikingly, engineered trimeric Nb457 nanobodies achieve complete inhibition against live HIV-1, outperforming Ibalizumab and parental Nb457, and shows therapeutic efficacy in humanized female mouse models. These findings highlight anti-CD4 nanobodies as promising HIV-1 therapeutics, with potential implications for advancing clinical treatment against this global health challenge.
Besides HIV-1, scientists from New York University Abu Dhabi have designed nanobodies against SARS-CoV-2 non-structural protein Nsp9, which is required for viral genome replication. One of these anti-Nsp9 nanobodies, 2NSP23, was encapsulated into lipid nanoparticles (LNP) as mRNA.?Their observations indicate that LNP-mRNA-2NSP23 is internalized and following translation, it inhibits viral replication by targeting Nsp9 in living cells. Therefore, it may be translated into an innovative strategy to generate novel antiviral drugs highly efficient across coronaviruses.
This week in the diagnostics field, researchers from University of Michigan Medical School developed a general method to screen nanobodies for cytochrome P450 enzymes from a yeast surface display library. Substitution of tight biotin-streptavidin binding for conventional primary and secondary antibodies allowed for a reduced screening cost and no further modification of protein. In the case of CYP102A1, they identified specific nanobodies that inhibit the catalytic activity with sub-micromolar affinity that may be useful for investigating the structure and function of P450 catalysis.
Upcoming Events?
Next month we will be exhibiting at the 15th World Bispecific Summit on September 3-5 in Boston, MA. The summit is the industry’s one-stop-shop for all your strategic needs within bi, tri or multi-specifics or even bispecific ADCs or BiTEs. Hosted by Hanson Wade Group and held at the Royal Sonesta Boston, we look forward to meeting you!?
领英推荐
Promotions – 40% OFF Abinvivo Products! ???
Save on Your Next Project with Abinvivo Reagents! Biointron is excited to announce a ????% ????????-???????? ???????????????? on our top-quality in vivo reagent products at the Biointron sub-brand, Abinvivo! Now with online check-out and 1 week delivery!?
????????'?? ????????????????:?
?? ?????? ???????????? ?????? ?????????????? ??????????????????
Don't miss out on this fantastic opportunity to enhance your research with top-tier reagents at unbeatable prices!
RushMab? - Gene is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
New Products & Reports?
Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340.